Drugs / PF-05089771
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05935280 | Jul → Sep 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT02349607 | Jan → Mar 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01934569 | Sep → Nov 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01854996 | May → Jun 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01772264 | Jan → Apr 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01690351 | Sep 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01563497 | Feb 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01529671 | Jan → Oct 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01365637 | Jun → Sep 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01259882 | Dec 2010 → Sep 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT02215252 | Nov 2014 → Jul 2015 | diabetic polyneuropathy | Pfizer | Completed | Missed primary |
| Phase 2 | NCT01769274 | Oct 2012 → Jul 2013 | primary erythermalgia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01529346 | Dec 2011 → Jun 2012 | — | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01165736 Comparator | Jul → Aug 2010 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05089771 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01365637 ↗ |
| Action | Inhibit | “Sodium channel protein type IX alpha subunit blocker” CHEMBL2325014 ↗1“blocked the Nav1.7 sodium channel” PMID 27099175 ↗ Apr 2016 |
| Modality | Small molecule | “treated with a new potent and selective compound that blocked the Nav1.7 sodium channel” PMID 27099175 ↗ Apr 2016 |
| Route | Intravenous | “single intravenous infusion of 100 microgram of PF-05089771” NCT01165736 ↗ |
| Target | SCN9A | “Sodium channel protein type IX alpha subunit blocker” CHEMBL2325014 ↗ |